Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanqitongfeng Capsule is a Traditional Chinese Medicine (TCM) formulation developed by the Kunming Institute of Nephrology for the treatment of acute gout flares. It is specifically indicated for patients exhibiting the 'blood stasis and phlegm-dampness' syndrome according to TCM diagnostic criteria. The formulation likely contains *Panax notoginseng* (Sanqi) as a primary component, which is traditionally used in Chinese medicine to resolve blood stasis, reduce swelling, and alleviate pain. The drug is currently being evaluated in Phase II randomized, double-blind, placebo-controlled clinical trials in China to assess its efficacy and safety in reducing the symptoms and inflammation associated with acute gout attacks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanqitongfeng Capsule.